Find in Library

Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis. While adverse skin reactions occur in 90% of patients treated with angiogenesis inhibitors, only a few cases of psoriasiform eruption associated with sorafenib therapy have been reported. We report a rare case of sorafenib-related psoriasis that responded well to topical treatment and narrow-band UV-B phototherapy after discontinuation of sorafenib.